We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Cambridge Cognition Holdings Plc | LSE:COG | London | Ordinary Share | GB00B8DV9647 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.50 | -0.91% | 54.50 | 54.00 | 55.00 | 54.50 | 54.50 | 54.50 | 20,004 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 12.61M | -409k | -0.0117 | -46.58 | 18.99M |
TIDMCOG
RNS Number : 9043D
Cambridge Cognition Holdings PLC
01 July 2019
Cambridge Cognition Holdings Plc
('Cambridge Cognition' or the 'Company')
Appointment of Non-Executive Director
The neuroscience technology company, Cambridge Cognition Holdings plc (AIM: COG), which develops and markets neuroscience technologies to assess brain health, is pleased to announce the appointment of Debra Leeves as a Non-Executive Director with immediate effect.
Debra is currently CEO of Vertual, the leading provider of virtual and augmented reality training simulation systems in radiotherapy. She has over 25 years of experience in the medical technology and biotechnology industries, and has previously been COO of Beckley Canopy Therapeutics, CEO of Physeon and also held senior roles with companies such as Rex Bionics, Avita Medical, Merck, GlaxoSmithKline, GE Healthcare and Pfizer.
Matthew Stork, CEO of Cambridge Cognition said:
"We are delighted that Debra has joined the Board. Debra brings with her an immense amount of knowledge and expertise in successful global medical technology businesses and clinical trial management within major pharmaceutical companies. Her experience will be invaluable as we continue the growth of Cambridge Cognition."
The following information regarding Debra Marie Leeves (aged 57) is disclosed under Schedule 2(g) of the AIM Rules for Companies:
Current Directorships Directorships held in past 5 years Vertual Limited Physeon GmbH Oxford Box Ltd DML Solutions Limited
As at the date of this announcement, Mrs Leeves is not beneficially interested in any Ordinary Shares in the Company.
There are no other matters which are required to be announced under Schedule 2(g) of the AIM Rules for Companies.
The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.
Enquiries
Cambridge Cognition Holdings PLC Matthew Stork, Chief Executive Officer Tel: 01223 810 700 Nick Walters, Chief Financial Officer press@camcog.com finnCap Ltd (NOMAD and Joint Broker) Tel: 020 7220 0500 Geoff Nash / Simon Hicks (Corporate Finance) Alice Lane / Manasa Patil (ECM) Dowgate Capital Limited (Joint Broker) Tel: 020 3903 7715 David Poutney / James Serjeant IFC Advisory Ltd (Financial PR and IR) Tel: 020 3934 6630 Tim Metcalfe / Miles Nolan / Zach Cohen
About Cambridge Cognition
Cambridge Cognition is a neuroscience technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early, and reduce global R&D and healthcare costs.
For further information visit www.cambridgecognition.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
MSCBUGDLCDDBGCI
(END) Dow Jones Newswires
July 01, 2019 02:00 ET (06:00 GMT)
1 Year Cambridge Cognition Chart |
1 Month Cambridge Cognition Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions